Fox Business - The Power to Prosper
Search Site

Allergan

Related Topics

  1. Food And Drug Administration
  2. Regeneron Pharmaceuticals
  3. Watson Pharmaceuticals
  4. Pharmaceuticals
  5. Julian Day
  6. Alan B. Miller
Get updates on Allergan
Allergan Reports Drug Development Delay, Lower Profits

Allergan Inc. (AGN) said it won't advance two of its key pipeline drugs into late stage trials needed for regulatory approval as quickly as it had hoped, sending the Botox maker's shares tumbling 12% and handing a big win to a competing drug maker.Chief Executive David Pyott said early data from a clinical study of its vision-loss drug DARPin don't merit moving the therapy into a late stage trial needed to gain approval from the U.S. Food and Drug Administration. The drug's eventual approval, still uncertain, will be delayed by one to two years, Mr. Pyott said, as the company conducts an additional midstage trial of the drug.Also, development of the company's experimental hair-loss treatment, Bimatoprost, will be delayed, the company said. The effectiveness of the drug in a mid stage trial doesn't warrant putting it into a late stage trial in the immediate future.Allergan made the disclosures during a conference call with analysts to discuss the company's first-quarter earnings, which ...

Read More ›

  1. Markets to Head Higher After a Short-Term Correction?

    Advisors Asset Management Senior V.P. Gene Peroni and Spectrum Management Group Managing Partner Bob Phillips on a potential market correction and stocks investors should consider for their portfolios.

  2. Allergan 4th-Quarter Profit Rose 16% Amid Growing Revenue, Fewer Charges

    Allergan Inc.'s (AGN) fourth-quarter earnings rose 16% as the botox-maker reported growing revenue and fewer one-time charges.For the year, the company projected per...

  3. Spectrum Pharma Regains Certain Rights to Apaziquone

    Biotechnology firm Spectrum Pharmaceuticals Inc. (SPPI) said it reacquired development and commercialization rights for apaziquone in the U.S., Europe and other terr...

  4. ‘Patent Cliff’ Not a Concern for Pharma Investors?

    Credit Suisse Managing Director Catherine Arnold on why it is a good time to invest in pharmaceutical companies.

  5. Allergan Looks to Boost Migraine Sales With MAP Purchase

    Botox-maker Allergan Inc. (AGN) doesn't want to be known as just a pretty face.The pharmaceutical firm famous for its cosmetic beauty products has agreed to pay $958...

  6. Botox Parent Allergan Buys MAP Pharma for $958M

    Botox maker Allergan (NYSE:AGN) agreed this week to buy MAP Pharmaceuticals (NASDAQ:MAPP) for just under $1.0 billion in cash as it looks to expand its reach in the ...

  7. Allergan Looks To Boost Migraine Sales With MAP Purchase

    Botox-maker Allergan Inc. (AGN) doesn't want to be known as just a pretty face.The pharmaceutical firm famous for its cosmetic beauty products has agreed to pay $958...

  8. Allergan to Buy MAP Pharmaceuticals for $958 Million

    Allergan Inc. (AGN) said Tuesday it will buy MAP Pharmaceuticals Inc. (MAPP) in a $958 million deal that would help the Botox maker expand sales of medical treatment...

  9. FDA Expands Approval of Botox to Treat Overactive Bladder

    The U.S. Food and Drug Administration has expanded the approved use of Allergan Inc.'s (AGN) Botox to treat adults with overactive bladders who don't respond to othe...

  10. Medical Device Makers: Repeal the New Tax!

    Starting January 1, medical-device makers must pay a new 2.3% excise tax on sales, regardless if they make a profit, to raise $30 billion over the next decade to pay...

  11. Allergan to Buy SkinMedica for $350 Million

    Allergan Inc. (AGN) said it agreed to buy SkinMedica Inc.'s topical-aesthetics skin-care business for $350 million to increase its presence in the skin-care market.T...

  12. Allergan Buying SkinMedica For Up To $375 Mln

    Allergan Inc. said Friday it'll pay up to $375 million to buy privately-held SkinMedica Inc. and its topical aesthetics skin care business. The acquisition does not ...

  1. Market Wrap for Wednesday, May 1: Stocks Fall as Employment Data Weakens in April

    The U.S. stock market was hit hard on Wednesday as investors reacted to a report which showed slowing employment conditions for the month of April.The losses were al...

  2. Allergan 1st-Quarter Profit Slumps Amid Expected Loss on Sale of Obesity Unit

    Allergan Inc.'s (AGN) first-quarter earnings slumped as the maker of face-wrinkle treatment Botox posted a disposal write-down of $259 million tied to its planned sa...

  3. FDA Warns of Counterfeit Botox

    Federal health authorities have found fake versions of Allergan Inc.'s (AGN) Botox in the U.S.The U.S. Food and Drug Administration said Friday the product may have ...

  4. FDA Doesn't Approve Allergan's Levadex for Migraines

    The U.S. Food and Drug Administration rejected Allergan Inc.'s (AGN) experimental inhalation treatment for migraines, a setback for the company after acquiring the d...

  5. FDA Doesn't Appove Allergan's Levadex for Migraines

    Allergan Inc. (AGN) said the U.S. Food and Drug Adminstration didn't approve its new drug application for its inhalable Levadex treatment for acute migraines in its ...

  6. Acadia Pharmaceuticals Permitted Quicker Path to Seek Approval for Antipsychotic Drug; Shares Surge

    Acadia Pharmaceuticals Inc. (ACAD) said in a surprise announcement that the U.S. Food and Drug Administration has allowed it to seek regulatory approval for its lead...

  7. Allergan CEO's 2012 Compensation Up 51% On Performance and Retention Award

    Allergan Inc.'s (AGN) chief executive officer saw a 51% increase in the value of his compensation for 2012 thanks to a large, one-time stock grant intended to reward...

‹ Prev123Next ›
Freebase CC-BY
Source: Allergan on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL